| scholarly article | Q13442814 |
| P50 | author | Randy J. Seeley | Q38546582 |
| Rohit Kohli | Q57014936 | ||
| Karen K Ryan | Q59297488 | ||
| Stephen C. Woods | Q110849828 | ||
| P2093 | author name string | Ruth Gutierrez-Aguilar | |
| Shrawan G Gaitonde | |||
| P2860 | cites work | Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21 | Q24318639 |
| FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis | Q24617480 | ||
| Central nervous system mechanisms linking the consumption of palatable high-fat diets to the defense of greater adiposity | Q26853424 | ||
| FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver | Q28512989 | ||
| Fundamentals of FGF19 & FGF21 action in vitro and in vivo | Q28729024 | ||
| Central nervous system control of food intake | Q29547439 | ||
| Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis | Q29619610 | ||
| Therapeutic utilities of fibroblast growth factor 19. | Q30407643 | ||
| Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models | Q30491274 | ||
| Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats | Q33930333 | ||
| Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity | Q34123954 | ||
| Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. | Q34197301 | ||
| Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. | Q34300009 | ||
| Consumption of a high-fat diet induces central insulin resistance independent of adiposity | Q34669531 | ||
| Fibroblast growth factor 21 corrects obesity in mice | Q34805555 | ||
| Mini-review: endocrine actions of fibroblast growth factor 19. | Q37052076 | ||
| Targeting the CNS to treat type 2 diabetes | Q37464738 | ||
| Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease | Q37781747 | ||
| Hormone-like fibroblast growth factors and metabolic regulation | Q37866879 | ||
| The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue | Q41912342 | ||
| FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway | Q42789527 | ||
| Effects of fibroblast growth factors and platelet-derived growth factor on food intake in rats | Q44730883 | ||
| Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys | Q46844955 | ||
| Identification of a hormonal basis for gallbladder filling. | Q47600731 | ||
| Modulation of metabolic syndrome by fibroblast growth factor 19 (FGF19)? | Q47611402 | ||
| Immunohistochemical localization in the rat brain of an epitope corresponding to the fibroblast growth factor receptor-1. | Q48136724 | ||
| Expression of new loci associated with obesity in diet-induced obese rats: from genetics to physiology | Q49022957 | ||
| Fibroblast growth factor receptor-1 in the lateral hypothalamic area regulates food intake | Q49149640 | ||
| The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo. | Q52596833 | ||
| A comprehensive analysis of the distribution of FGF-2 and FGFR1 in the rat brain | Q56427932 | ||
| Fibroblast growth factor-19 levels in type 2 diabetic patients with metabolic syndrome | Q82939022 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | glucose | Q37525 |
| glycobiology | Q899224 | ||
| P304 | page(s) | 9-15 | |
| P577 | publication date | 2012-11-26 | |
| P1433 | published in | Endocrinology | Q3054009 |
| P1476 | title | Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats | |
| P478 | volume | 154 |
| Q37431303 | A Genetic Screen Identifies Hypothalamic Fgf15 as a Regulator of Glucagon Secretion. |
| Q88802483 | Are Tanycytes the Missing Link Between Type 2 Diabetes and Alzheimer's Disease? |
| Q35564937 | Bariatric surgery: prevalence, predictors, and mechanisms of diabetes remission |
| Q47135121 | Bile Acid Signaling Pathways from the Enterohepatic Circulation to the Central Nervous System |
| Q35737058 | Bile Acids as Hormones: The FXR-FGF15/19 Pathway |
| Q47134180 | Bile acids at the cross-roads of gut microbiome-host cardiometabolic interactions. |
| Q90731281 | Bile acids in glucose metabolism and insulin signalling - mechanisms and research needs |
| Q48042610 | Bile acids in glucose metabolism in health and disease |
| Q26865811 | Brain regulation of energy balance and body weight |
| Q37554768 | Carbohydrate feeding dissociates the postprandial FGF19 response from circulating bile acid levels in humans |
| Q41959673 | Central action of FGF19 reduces hypothalamic AGRP/NPY neuron activity and improves glucose metabolism |
| Q37079786 | Central injection of fibroblast growth factor 1 induces sustained remission of diabetic hyperglycemia in rodents |
| Q37698362 | Cooperation between brain and islet in glucose homeostasis and diabetes |
| Q37699321 | Digestive physiology of the pig symposium: intestinal bile acid sensing is linked to key endocrine and metabolic signaling pathways |
| Q91891093 | Dissecting the Brain/Islet Axis in Metabesity |
| Q57112246 | Divergent effects of resistance and endurance exercise on plasma bile acids, FGF19, and FGF21 in humans |
| Q93184566 | Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases |
| Q90640205 | Enteric Microbiota⁻Gut⁻Brain Axis from the Perspective of Nuclear Receptors |
| Q98906651 | FGF/FGFR signaling in health and disease |
| Q39406663 | FGF1 - a new weapon to control type 2 diabetes mellitus |
| Q35549802 | FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic-pituitary-adrenal axis |
| Q37259301 | FGF19 action in the brain induces insulin-independent glucose lowering |
| Q47183309 | FGF19, FGF21, and an FGFR1/β-Klotho-Activating Antibody Act on the Nervous System to Regulate Body Weight and Glycemia |
| Q41826321 | FGF19: How gut talks to brain to keep your sugar down |
| Q26772751 | Fibroblast Growth Factor Signaling in Metabolic Regulation |
| Q42920547 | Fibroblast growth factor 19 entry into brain |
| Q38325739 | Fibroblast growth factor 19-targeted therapies for the treatment of metabolic disease |
| Q35929495 | Glucose intolerance induced by blockade of central FGF receptors is linked to an acute stress response |
| Q92106368 | Gut Microbiome and Modulation of CNS Function |
| Q30235568 | Gut-Brain Cross-Talk in Metabolic Control |
| Q35029601 | Gut-brain mechanisms controlling glucose homeostasis |
| Q36281648 | Impact of gut hormone FGF-19 on type-2 diabetes and mitochondrial recovery in a prospective study of obese diabetic women undergoing bariatric surgery |
| Q38105423 | Integration of satiety signals by the central nervous system |
| Q92687518 | Inter-organ communication: a gatekeeper for metabolic health |
| Q36935411 | Link Between Increased Satiety Gut Hormones and Reduced Food Reward After Gastric Bypass Surgery for Obesity |
| Q38120144 | Mechanisms underlying weight loss after bariatric surgery |
| Q97643831 | Metabolic Messengers: fibroblast growth factor 15/19 |
| Q36237911 | Metabolic effects of intestinal absorption and enterohepatic cycling of bile acids |
| Q36746670 | Metabolic fibroblast growth factors (FGFs): Mediators of energy homeostasis |
| Q36107291 | Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases |
| Q37712631 | Non-Neuronal Cells in the Hypothalamic Adaptation to Metabolic Signals |
| Q28659292 | Obese patients after gastric bypass surgery have lower brain-hedonic responses to food than after gastric banding. |
| Q90315934 | Peripheral Mechanisms Mediating the Sustained Antidiabetic Action of FGF1 in the Brain |
| Q92763064 | Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis |
| Q97551469 | Projections from the Dorsomedial Division of the Bed Nucleus of the Stria Terminalis to Hypothalamic Nuclei in the Mouse |
| Q26745203 | Recent advances in metabolic and bariatric surgery |
| Q94560979 | Regulation of Energy Metabolism by Receptor Tyrosine Kinase Ligands |
| Q35836340 | Regulation of bile acid homeostasis by the intestinal Diet1-FGF15/19 axis |
| Q92252696 | Role of the intestinal microbiome in liver fibrosis development and new treatment strategies |
| Q57294546 | Roles of Gut-Derived Secretory Factors in the Pathogenesis of Non-Alcoholic Fatty Liver Disease and Their Possible Clinical Applications |
| Q87842301 | Signalling from the periphery to the brain that regulates energy homeostasis |
| Q57109419 | Targeting FXR and FGF19 to Treat Metabolic Diseases-Lessons Learned From Bariatric Surgery |
| Q26738730 | Targeting the gastrointestinal tract to treat type 2 diabetes |
| Q35577851 | Temporal changes in bile acid levels and 12α-hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes. |
| Q57120648 | The Brain-Gut-Microbiome Axis |
| Q38913696 | The Contributing Role of Bile Acids to Metabolic Improvements After Obesity and Metabolic Surgery |
| Q57186276 | The Gut-Brain Axis and the Microbiome: Mechanisms and Clinical Implications |
| Q30234616 | The Role and Potential Therapeutic Implications of the Fibroblast Growth Factors in Energy Balance and Type 2 Diabetes |
| Q91951425 | The central fibroblast growth factor receptor/beta klotho system: Comprehensive mapping in Mus musculus and comparisons to nonhuman primate and human samples using an automated in situ hybridization platform |
| Q38123372 | The endocrinology of food intake |
| Q35665486 | The role of bile acids in reducing the metabolic complications of obesity after bariatric surgery: a systematic review. |
| Q38633258 | Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. |
| Q34778879 | Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. |
Search more.